Glepaglutide
Phase 3Active 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Short Bowel Syndrome
Conditions
Short Bowel Syndrome
Trial Timeline
Jun 16, 2021 → Apr 1, 2026
NCT ID
NCT04881825About Glepaglutide
Glepaglutide is a phase 3 stage product being developed by Zealand Pharma for Short Bowel Syndrome. The current trial status is active. This product is registered under clinical trial identifier NCT04881825. Target conditions include Short Bowel Syndrome.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (7)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07197944 | Phase 3 | Recruiting |
| NCT04991311 | Phase 3 | Completed |
| NCT04881825 | Phase 3 | Active |
| NCT04318743 | Phase 1 | Completed |
| NCT04178447 | Phase 1 | Completed |
| NCT03905707 | Phase 3 | Active |
| NCT03279302 | Phase 1 | Completed |
Competing Products
20 competing products in Short Bowel Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| somatropin + leuprorelin | Eli Lilly | Phase 3 | 77 |
| Growth Hormone | Eli Lilly | Approved | 85 |
| Pancreatic Enzyme | AbbVie | Phase 2 | 52 |
| Aromatase Inhibitor + Growth Hormone + Aromatase Inhibitor and Growth Hormone | AstraZeneca | Phase 3 | 77 |
| Oral, live, pentavalent rotavirus vaccine; RotaTeq(R) | Merck | Phase 1 | 33 |
| Saizen® + Saizen® | Merck | Phase 3 | 77 |
| r-metHuLeptin | Amgen | Phase 1 | 32 |
| Somapacitan + Norditropin® | Novo Nordisk | Phase 2 | 51 |
| Somatotropin growth hormone recombinant human | Pfizer | Approved | 84 |
| Genotropin (somatropin) | Pfizer | Approved | 84 |
| Genotropin + Genotropin | Pfizer | Phase 3 | 76 |
| GH treatment (Genotropin) + 1 year treatment with placebo followed by optional 3 years of GH treatment | Pfizer | Approved | 84 |
| Genotropin | Pfizer | Phase 2/3 | 64 |
| glepaglutide | Zealand Pharma | Phase 3 | 74 |
| ZP1848 | Zealand Pharma | Phase 2 | 49 |
| glepaglutide + Placebo | Zealand Pharma | Phase 3 | 74 |
| Glepaglutide | Zealand Pharma | Phase 3 | 74 |
| Glepaglutide 10 mg | Zealand Pharma | Phase 3 | 74 |
| Glepaglutide | Zealand Pharma | Phase 3 | 74 |
| Nutropin [Somatropin (rDNA origin) for injection] | Ipsen | Approved | 82 |